Press Releases Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-06-13 EDT			5-day change	1st Jan Change
451.40 ^DKK	-4.85%		-5.25%	-36.91%

06-13	Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	RE
06-11	Zealand Pharma A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 04:00 PM

Press Releases

Zealand Pharma increases its share capital as a result of the exercise of employee warrants	06-06	GL
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome	06-02	GL
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome	06-02	AQ
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	05-27	GL
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer	05-19	GL
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025	05-12	GL
Zealand Pharma announces closing of collaboration and license agreement with Roche	05-09	GL
Zealand Pharma A/S : Interim Report Q1 2025	05-08	PU
Zealand Pharma Announces Financial Results for the First Three Months of 2025	05-08	GL
Zealand Pharma Announces Financial Results for the First Three Months of 2025	05-08	AQ
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results	05-01	GL
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results	05-01	AQ
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes	04-24	GL
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes	04-24	AQ
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery	04-23	GL
Zealand Pharma A/S : launches long-term incentive programs for 's Board of Directors, Corporate Management and employees for 2025	04-19	PU
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	04-19	AQ
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	04-19	GL
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025	04-19	AQ
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025	04-19	GL
Resolutions from Zealand Pharma's Annual General Meeting 2025	03-27	GL
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.	03-25	GL
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.	03-25	AQ
Zealand Pharma increases its share capital as a result of the exercise of employee warrants	03-20	GL
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity	03-17	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Press Releases

Filters